Australia & Australia — Therapeutic Goods Administration

Australia: Australia is the market where 4DMedical Limited's CT:VQ technology has received TGA approval, enabling its commercial deployment and expanding access to functional lung imaging across the country.

Australia — Therapeutic Goods Administration: The Australia — Therapeutic Goods Administration granted approval for 4DMedical Limited's CT:VQ technology, allowing its commercial deployment in Australia. This regulatory body's decision is crucial for market access.

Australia: Australia is the recipient country for Optimi Health's psilocybin capsules, providing a regulated market for the treatment of treatment-resistant depression and setting a model for psychedelic medicine use.

Australia — Therapeutic Goods Administration: The Australia — Therapeutic Goods Administration in Australia oversees the Authorized Prescriber Scheme, under which Optimi Health's psilocybin is prescribed and reimbursed, facilitating patient access to psychedelic medicine.